The Immunotherapy Revolution: Towards Future Cancer Treatments

After watching this webinar, participants will understand: how an artificial intelligence algorithm for implantable cardiac monitors is developed and validated; and the reliability of this approach and how it may result in a more efficient hospital workflow.

COVID-19 represents a global crisis, yet significant knowledge gaps remain about human immunity to SARS-CoV-2. As many researchers raced to develop the vaccines and therapeutics needed to mitigate the pandemic, other investigators took up the task of understanding the human body’s diverse response to this virus. With technology advancing exponentially, researchers have an arsenal of analytic tools now at their disposal to decipher the most elusive aspects of viral immunobiology.

CMIC Group, the first and largest CRO in Japan with extended services in drug development and GMP manufacturing in the US, Japan and Asia, held a webinar Advanced ODT Technologies for Drug Development in Japan and the US on April 11, 2019.Since its introduction in the 1980s, the market of orally disintegrating tablet (ODT) has grown annually and ODTs are now available in a variety of therapeutic areas, both over-the-counter (OTC) and by prescription. ODT market is projected to reach US$21B in 2023.In this webinar, CMIC and Aprecia experts talked about advanced ODT technologies and its advantages in drug development.

Tumor heterogeneity is a major hurdle for cancer treatment success. To effectively enroll patients in clinical trials, the identification of predictive biomarkers at the preclinical stage is crucial. The use of patient-derived xenograft (PDX) tumor models facilitates the identification of biomarkers that predict the tumor’s response to therapy. In addition, the assessment of PDX models on broad screening platforms such as 3D culture and in vivo mouse clinical trials (humanized and immunodeficient) accelerates compound evaluation. This webinar discusses the use of PDX models in preclinical drug development and the benefits of using this approach to clinical trial outcomes. Click below to view the slides of the presentation.